ASCO 2018

Viewing 1-20 of 26 articles

ASCO 2018: Relapse-Free Survival of Clinical T2-4N0 Urothelial Bladder Carcinoma After Radical Cystectomy, with or without Perioperative Chemotherapy: Endpoints for Clinical Trial Design.

ASCO 2018: Optimization of PD-L1 Algorithm for Predicting OS in Patients with Urothelial Cancer Treated with Durvalumab

ASCO 2018: Tailoring of Chemotherapy to Fit Patients with Metastatic Urothelial Cancer

ASCO 2018: Targeted Therapies in Advanced Urothelial Cancer

ASCO 2018: Immunotherapy-Based Approaches for Advanced Urothelial Cancer

ASCO 2018: SPEAR-Bladder (Study Informing Treatment Pathway Decision in Bladder Cancer): First-Through Third-Line Time to Treatment Failure in the US

ASCO 2018: Bladder Cancer and Germ Cell Tumors

ASCO 2018: Nonimmunotherapy Strategies in Advanced Bladder Cancer

ASCO 2018: A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer (ABACUS)

ASCO 2018: Preoperative Pembrolizumab Before Radical Cystectomy for Muscle-Invasive Urothelial Bladder Carcinoma: Interim Clinical and Biomarker Findings from the Phase 2 PURE-01 Study

ASCO 2018: Cctg BL12: Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing On or After a Platinum Containing Regimen

ASCO 2018: PECULIAR: An Open Label, Multicenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat, Preceding Radical Cystectomy, for Patients with Muscle-invasive Urothelial Bladder Cancer

ASCO 2018: Updated Results from the Enfortumab Vedotin Phase 1 (EV-101) Study in Patients with Metastatic Urothelial Cancer

ASCO 2018: First Results from the Primary Analysis Population of the Phase 2 Study of Erdafitinib in Patients with Metastatic or Unresectable Urothelial Carcinoma and FGFR Alterations

ASCO 2018: SPIRE: A Phase 1b/Randomized 2a Open Label Clinical Trial Combining Guadecitabine (SGI-110) with Cisplatin and Gemcitabine Chemotherapy for Solid Malignancies Including Bladder Cancer

ASCO 2018: Atezolizumab in First-Line Cisplatin-Ineligible or Platinum Treated Locally Advanced or Metastatic Urothelial Cancer: Long-Term Efficacy from Phase 2 Study IMvigor210

ASCO 2018: BMS-986205, an IDO1 Inhibitor, in Combination with Nivolumab: Updated Safety Across all Tumor Cohorts and Efficacy in Patients with Advanced Bladder Cancer

ASCO 2018: Apache: Open Label, Randomized, Phase 2 Study of Durvalumab, Alone or in Combination with Tremelimumab, in Patients with Advanced Germ Cell Tumors: Results at the End of First Stage

ASCO 2018: Pembrolizumab versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer: 2-Year Follow-Up from KEYNOTE-045 Trial

ASCO 2018: A Subgroup Analysis of the East Asia Population in RANGE

1
2

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.